StockData

Acro Biomedical Co., Ltd. (ACBM) stock

ACBMOTCServices-Amusement & Recreation ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $1.56MP/E –Yield –

Acro Biomedical Co., Ltd. reported revenue of $0 for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $1.56M.

Revenue
$0
TTM Q2 2026
Operating income
-$209.30K
TTM Q2 2026
EPS, diluted
$0.00
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$1.56M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$140.41K
EPS, diluted
$0.00
Book value per share
-$0.01
Diluted shares
60M

Trading

Previous close
$0.03
Open
$0.03
Day's range
$0.03 – $0.03
Volume
0

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodACBMS&P 500DifferenceACBM per yearS&P 500 per year
1 month0.0%+0.6%−0.6 pts
3 months0.0%+3.4%−3.4 pts
Year to date+17.1%+13.3%+3.8 pts
1 year+3614.3%+16.6%+3597.7 pts
3 years-98.3%+86.4%−184.6 pts-74.1%+23.1%
5 years-99.4%+81.9%−181.3 pts-64.3%+12.7%

Eleven years at a glance

Fiscal years 2014 to 2025 and trailing twelve months, USD

Revenue

$0

Gross profit

–

Operating income

-$209.30K

Net income

-$140.41K

EPS, diluted

$0.00
Reported periodTrailing twelve months

About Acro Biomedical

Services-Amusement & Recreation Services

Acro Biomedical Co., Ltd., formerly known as Killer Waves Hawaii, Inc., develops and markets nutritional wellness products centered on cordyceps, a parasitic fungus traditionally utilized in Chinese medicine. Historically, the company has purchased inventory from suppliers in Taiwan to sell in bulk to commercial customers, including distributors. These clients either resell the products directly or incorporate them as ingredients into finished goods. The company has also previously sold metallothionein MT-3 elizer and explored developing cordyceps-based chicken feed, though it does not package or offer items directly for retail consumer use.

Company profile, executives and history

Acro Biomedical stock: common questions

What is Acro Biomedical's stock price?

ACBM closed at $0.03 on Oct 19, 2026, up 0.00% on the day.

What is Acro Biomedical's market cap?

Acro Biomedical was worth $1.56M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is ACBM's P/E ratio?

Acro Biomedical lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

How much revenue does Acro Biomedical make?

Acro Biomedical reported revenue of $0 for the twelve months to Jun 30, 2026.

Does Acro Biomedical pay a dividend?

No. Acro Biomedical has not paid a cash dividend over the last twelve months.

How has ACBM stock performed over the past year?

Including dividends, ACBM returned +3614.3% over the past year, against +16.6% for the S&P 500.

Who are Acro Biomedical's competitors?

Companies most similar to Acro Biomedical by business, industry and size include LAAI, TONT, LVRLF, CPOP, FLZH.

See a number that looks wrong?